Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adrenal Gland Neoplasms × pertuzumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1 Neuroblastoma 1 Multiple Endocrine Neoplasia 1 Carcinoid Tumor 1 Adrenal Gland Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 2 Fluorodeoxyglucose F18 2 FAPI-46 2 pertuzumab 1 olaparib 1 lutetium Lu 177 dotatate 1 Nivolumab 1 Erlotinib Hydrochloride 1 Cryosurgery 1 (18F)GTP1 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated

4 enrolled 5 charts

CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡